[Skip to Navigation]
Apr 2012

Topical Psoralen Plus UV-A Therapy for Tyrosine Kinase Inhibitor–Induced Hand-Foot Syndrome

Author Affiliations

Author Affiliations: Department of Dermatology, Erasmus University Medical Center, Rotterdam, the Netherlands (Drs Bos and Nijsten); Department of Medical Oncology, Erasmus University Medical Center–Daniel den Hoed Cancer Center, Rotterdam (Drs de Jonge and Hamberg).

Arch Dermatol. 2012;148(4):546-547. doi:10.1001/archdermatol.2011.3482

Because the number of patients with solid malignant neoplasms treated with multiple tyrosine kinase inhibitors (TKIs) is increasing rapidly, treatment of the adverse effects of the drug is of utmost importance. The treatment is aimed at prolonging life, but hand-foot syndrome (HFS) is a well-known cutaneous adverse effect,1 clinically characterized by palmar- and plantar-symmetric, sharply demarcated erythema and desquamation with pain, dysesthesia, paresthesia, and temperature intolerance. The severity of HFS sometimes necessitates a dose reduction or complete discontinuation of treatment.

Add or change institution